In short
Recent clinical trials are investigating the potential of Cannabis Sativa Flower as a treatment for diabetic peripheral neuropathic pain (DPNP). This study focuses on using a medical cannabis aerosol delivered through the Syqe Inhaler, a fixed-dose device. The research aims to evaluate the efficacy and safety of different doses of THC (tetrahydrocannabinol) compared to a placebo in managing pain intensity for patients with DPNP.
At a glance
- Study Design
- Double-blind, randomized, placebo-controlled, 4-arm parallel-group
- Condition
- Diabetic Peripheral Neuropathic Pain (DPNP)
- Intervention
- Cannabis Sativa L. 'Afina' inflorescence aerosol via Syqe Inhaler
- Dosages
- 0 mg (placebo), 0.25 mg, 0.5 mg, 1.0 mg of Δ9-THC
- Administration
- Inhaled three times daily (TID)
- Duration
- 19 weeks (14 days screening, 15 weeks treatment, 4 weeks follow-up)
- Primary Endpoint
- Change in weekly-mean 24-hour average pain score at Week 15
- Key Inclusion Criteria
- Ages 18-75, diagnosed DPNP, stable diabetes treatment, pain intensity ≥4 and ≤9 on NRS
- Key Exclusion Criteria
- Recent cannabis use, substance abuse, significant uncontrolled diseases, abnormal liver/kidney function
What is Cannabis Sativa Flower?
Cannabis Sativa Flower, also known as Cannabis flower or Cannabis sativa flos, is a medicinal plant product being studied for its potential therapeutic benefits. The main active ingredient in this treatment is Δ9-tetrahydrocannabinol (THC), which is one of the primary compounds found in cannabis plants known for its medicinal properties.
Medical Condition Treated
The primary focus of the current research is on treating Diabetic Peripheral Neuropathic Pain (DPNP). This is a type of nerve pain that affects people with diabetes. It typically causes a burning, tingling, or shooting pain in the feet and legs, and sometimes in the hands and arms. This pain is a result of nerve damage caused by prolonged high blood sugar levels in diabetic patients.
How It's Administered
The Cannabis Sativa Flower is administered as an aerosol using a special device called the Syqe Inhaler. This is a fixed-dose inhaler system that allows for precise dosing of the medication. The system consists of three parts:
- The Syqe Fixed-dose Inhaler
- Syqe Cartridge (containing the medication)
- Syqe Mouthpiece
This method of administration allows for quick absorption of the medication through the lungs, potentially providing faster relief compared to other forms of cannabis-based treatments.
Dosage and Treatment
In the ongoing clinical trial, researchers are testing three different doses of THC: 0.25 mg, 0.5 mg, and 1.0 mg. These doses are administered three times a day (TID). The maximum daily dose being tested is 3 mg, and the treatment period lasts for about 15 weeks.
Efficacy and Benefits
The main goal of this treatment is to reduce pain intensity in patients with DPNP. Researchers are evaluating its effects on:
- Average, worst, and least pain intensity
- Pain characteristics and severity
- Quality of life
- Sleep disturbances related to pain
The study aims to determine if this treatment can provide significant pain relief compared to a placebo when added to standard care for DPNP.
Safety and Side Effects
As with any medication, safety is a primary concern. The ongoing study is closely monitoring for any side effects or adverse reactions. Some areas being watched include:
- General adverse events and their severity
- Effects on mental health (using tools like the Columbia-Suicide Severity Rating Scale)
- Impacts on lung function (through spirometry tests)
- Effects on heart function (via electrocardiogram)
- Changes in blood and urine tests
It's important to note that this treatment may affect your ability to drive or operate heavy machinery, and patients in the study are advised against these activities during the treatment period.
Who Can Use This Treatment
This treatment is still in the research phase and not yet available for general use. In the current study, eligible participants are:
- Adults aged 18 to 75 years
- Diagnosed with diabetes (Type I or II) with stable blood sugar control
- Experiencing DPNP for at least 6 months
- Already on standard care for DPNP (such as duloxetine, gabapentin, or pregabalin)
- Not current users of cannabis products
There are several exclusion criteria, including certain medical conditions, medications, and lifestyle factors. Always consult with a healthcare provider to determine if a treatment is appropriate for you.
Ongoing Research
This treatment is currently being studied in a clinical trial. The research aims to determine its effectiveness, optimal dosage, and safety profile. The study is also looking at how the body processes the medication (pharmacokinetics) and its effects on various aspects of patients' lives, including sleep quality and overall well-being.
It's important to remember that while this treatment shows promise, it is still in the research phase. More studies will be needed to fully understand its benefits and risks before it can be considered for wider use in treating DPNP.